Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

References

1. 1.↵
   2. Hurwitz H,
   3. Fehrenbacher L,
   4. Novotny W,
   5. Cartwright T,
   6. Hainsworth J,
   7. Heim W, et al.

   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–42.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   2. Sandler A,
   3. Gray R,
   4. Perry MC,
   5. Brahmer J,
   6. Schiller JH,
   7. Dowlati A, et al.

   Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542–50.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Cameron D,
   3. Brown J,
   4. Dent R,
   5. Jackisch C,
   6. Mackey J,
   7. Pivot X, et al.

   Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013; 14: 933–42.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Huang HY,
   3. Wu DW,
   4. Ma F,
   5. Liu ZL,
   6. Shi JF,
   7. Chen X, et al.

   Availability of anticancer biosimilars in 40 countries. Lancet Oncol. 2020; 21: 197–201.

   OpenUrl
5. 5.↵
   2. Lyman GH,
   3. Zon R,
   4. Harvey RD,
   5. Schilsky RL.

   Rationale, opportunities, and reality of biosimilar medications. N Engl J Med. 2018; 378: 2036.

   OpenUrl
6. 6.↵
   2. Santos SB,
   3. Lobo JMS,
   4. Silva AC.

   Biosimilar medicines used for cancer therapy in Europe: a review. Drug Discov Today. 2019; 24: 293–9.

   OpenUrl
7. 7.↵
   2. Thatcher N,
   3. Goldschmidt JH,
   4. Thomas M,
   5. Schenker M,
   6. Pan Z,
   7. Rodriguez LPA, et al.

   Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019; 25: 2088–95.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Liu YN,
   3. Huang J,
   4. Guo C,
   5. Yang S,
   6. Ye L,
   7. Wu S, et al.

   A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Cancer Chemoth Pharmacol. 2020; 85: 555–62.

   OpenUrl
9. 9.↵
   2. Reinmuth N,
   3. Bryl M,
   4. Bondarenko I,
   5. Syrigos K,
   6. Vladimirov V,
   7. Zereu M, et al.

   PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin®), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study. Biodrugs. 2019; 33: 555–70.

   OpenUrl
10. 10.↵
    2. Cho SH,
    3. Han S,
    4. Ghim JL,
    5. Nam MS,
    6. Yu S,
    7. Park T, et al.

    A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. Biodrugs. 2019; 33:173–81.

    OpenUrl
11. 11.↵
    2. Casak SJ,
    3. Lemery SJ,
    4. Chung J,
    5. Fuchs C,
    6. Schrieber SJ,
    7. Chow EC, et al.

    FDA’s approval of the first biosimilar to bevacizumab. Clin Cancer Res. 2018; 24: 4365–70.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Jemal A,
    3. Bray F,
    4. Center MM,
    5. Ferlay J,
    6. Ward E,
    7. Forman D.

    Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.

    Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Han BH,
    3. Li K,
    4. Wang QM,
    5. Zhang L,
    6. Shi J,
    7. Wang Z, et al.

    Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018; 4: 1569–75.

    OpenUrl
15. 15.
    2. Lu J,
    3. Zhong H,
    4. Chu TQ,
    5. Zhang X,
    6. Li R,
    7. Sun J, et al.

    Role of anlotinib-induced CCL2 decrease in antiangiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. 2019; 53: 1801562.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    2. Lu J,
    3. Zhong H,
    4. Wu J,
    5. Chu T,
    6. Zhang L,
    7. Li H, et al.

    Circulating DNA-based sequencing guided anlotinib therapy in non-small cell lung cancer. Adv Sci. 2019; 6: 1900721.

    OpenUrl
17. 17.↵
    2. Rugo HS,
    3. Barve A,
    4. Waller CF,
    5. Hernandez-Bronchud M,
    6. Herson J,
    7. Yuan J, et al.

    Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017; 317: 37–47.

    OpenUrl
18. 18.↵
    2. Jurczak W,
    3. Moreira I,
    4. Kanakasetty GB,
    5. Munhoz E,
    6. Echeveste MA,
    7. Giri P, et al.

    Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017; 4: e350–e61.

    OpenUrl
19. 19.↵
    2. Zhou C,
    3. Wu Y,
    4. Chen G,
    5. Feng J,
    6. Liu XQ,
    7. Wang C, et al.

    Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015; 26: 1877–83.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Dogan S,
    3. Shen R,
    4. Ang DC,
    5. Johnson ML,
    6. D’Angelo SP,
    7. Paik PK, et al.

    Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012; 18: 6169–77.

    OpenUrlAbstract/FREE Full Text